New research suggests cruise ship pollution may increase inflammation and weaken the body's defenses against viruses.
Eleven new molecular drug targets receive approval in 2025, expanding treatment options for rare diseases, cancer, and infectious diseases.
Atea Pharma initiates first-in-human phase 1 trial of AT-587 for the treatment of hepatitis E virus: Boston Thursday, July 16, 2026, 15:00 Hrs [IST] Atea Pharmaceuticals, Inc., a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results